Filana Therapeutics (FLNA) Financials
Ticker history: SAVA became FLNA (Filana Therapeutics, Inc.) on . Earlier news and filings retain their original names and dates. View SAVA history.
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 4, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 10-Q for Q2 FY2026, filed Jul 29, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the FLNA SEC filings page.
This page shows Filana Therapeutics, Inc. (FLNA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings.
Filana remains a cash-consuming research business, with FY2025 financing pressure sharply weakening its balance-sheet cushion.
In FY2025, the company reported a net loss of$91.0M alongside operating cash flow of-$32.3M , so earnings and cash movement diverged. That contrasts with FY2024, when the net loss was$24.3M but operating cash flow was-$116.9M , showing that reported losses alone do not describe annual cash use.
Compared with FY2023, R&D fell 70.3% while SG&A rose 316.1%, shifting reported spending away from research and toward overhead. That mix change did not produce positive operating results: FY2025 operating loss was
FY2025 liabilities rose
Financial Health Signals
We do not publish a peer-relative financial health score for Filana Therapeutics, Inc., because the score only covers companies whose filings and listing give us what it needs to compare them with their peers. The signals and metrics below are current.
Filana Therapeutics, Inc. passes 2 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
Filana Therapeutics, Inc. reported a net loss of $91.0M while operations used $32.3M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Filana Therapeutics, Inc.'s EBITDA was -$9.1M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Filana Therapeutics, Inc. reported a net loss of $8.6M in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q2 2026.
Not reported for Q2 2026.
Cash & Balance Sheet
Filana Therapeutics, Inc. recorded an outflow of $3.9M in free cash flow in Q2 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.
Filana Therapeutics, Inc. held $82.7M in cash as of Q2 2026; no long-term debt figure is on record for that period.
Not reported for Q2 2026.
Margins & Returns
Filana Therapeutics, Inc.'s quarterly ROE was -13.5% in Q2 2026: one quarter's net income over shareholder equity, not annualized. This is up 36.8 percentage points from the same quarter a year earlier. Against the prior quarter it is up 1.6 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
Filana Therapeutics, Inc. invested $3.3M in research and development in Q2 2026. This represents a decrease of 35.4% from the same quarter a year earlier. Against the prior quarter it is down 27.3%.
Filana Therapeutics, Inc. invested $21K in capex in Q2 2026, funding long-term assets and infrastructure. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative.
Not reported for Q2 2026.
FLNA Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'25Filing | Q2'25Filing | Q1'2510-Q | Q4'24Filing | Q3'24Filing |
|---|---|---|---|---|---|---|---|---|
| R&D Expenses | $3.3M-35.4% | $4.5M-66.7% | $3.9M-81.2% | $4.0M-77.6% | $5.1M-66.3% | $13.7M-15.8% | $20.5M+9.6% | $17.7M-25.1% |
| SG&A Expenses | $6.1M-84.9% | $6.6M-39.3% | $9.7M+8.3% | $7.9M-38.9% | $40.3M-12.8% | $10.9M+195.1% | $9.0M+120.7% | $12.9M+202.8% |
| Operating Income | -$9.4Mn/m | -$11.2Mn/m | -$13.6Mn/m | -$11.9Mn/m | -$45.4Mn/m | -$24.6Mn/m | -$29.5Mn/m | -$30.6Mn/m |
| EBITDA | -$9.1Mn/m | -$10.9Mn/m | N/A | -$11.7Mn/m | -$45.2Mn/m | -$24.4Mn/m | N/A | -$30.4Mn/m |
| Income Tax | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0 | $0n/m |
| Net Income | -$8.6Mn/m | -$10.3Mn/m | -$12.5Mn/m | -$10.8Mn/m | -$44.2M-818.5% | -$23.4M-193.5% | -$27.6Mn/m | -$27.9Mn/m |
| EPS (Basic) | -$0.18n/m | -$0.21n/m | -$0.26n/m | -$0.22n/m | -$0.92-807.7% | -$0.48-182.8% | -$0.60n/m | -$0.58n/m |
| EPS (Diluted) | N/A | N/A | -$0.26n/m | -$0.22n/m | -$0.92-807.7% | -$0.48n/m | -$0.58n/m | -$0.58n/m |
| Diluted Shares (Avg) | N/A | N/A | N/A | 48M+0.7% | 48M+4.6% | 48M+9.4% | N/A | 48M+14.2% |
Not reported in any period shown, so not listed: Revenue, Cost of Revenue, Gross Profit, Interest Expense.
FLNA Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'25Filing | Q2'25Filing | Q1'2510-Q | Q4'24Filing | Q3'24Filing |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $103.9M-23.3% | $108.4M-23.1% | $118.4M-24.9% | $129.7M-42.0% | $135.4M-44.4% | $140.9M-9.5% | $157.5M+3.9% | $223.8M+29.7% |
| Current Assets | $83.7M-27.1% | $88.0M-26.8% | $97.7M-28.4% | $108.9M-46.2% | $114.8M-48.3% | $120.2M-10.3% | $136.5M+5.3% | $202.5M+34.9% |
| Cash & Equivalents | $82.7M-26.4% | $86.6M-26.2% | $95.5M-25.7% | $106.1M-28.8% | $112.4M-45.8% | $117.3M-5.5% | $128.6M+6.1% | $149.0M+4.7% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $40.3M-15.0% | $40.2M+202.1% | $44.0M+271.6% | $48.2M-15.7% | $47.4M-13.2% | $13.3M-82.7% | $11.8M-16.7% | $57.1M+228.0% |
| Current Liabilities | $40.2M-15.2% | $40.1M+203.1% | $43.8M+273.1% | $48.0M-15.8% | $47.3M-13.3% | $13.2M-82.8% | $11.8M-17.2% | $57.0M+227.5% |
| Non-Current Liabilities | $136K+72.2% | $111K+40.5% | $118K+49.4% | $119K+48.8% | $79Kn/m | $79Kn/m | $79Kn/m | $80Kn/m |
| Total Equity | $63.6M-27.7% | $68.1M-46.6% | $74.4M-48.9% | $81.6M-51.1% | $88.0M-53.4% | $127.6M+62.4% | $145.7M+6.0% | $166.6M+7.4% |
| Retained Earnings | -$515.0Mn/m | -$506.4Mn/m | -$496.1Mn/m | -$483.5Mn/m | -$472.7Mn/m | -$428.5Mn/m | -$405.1Mn/m | -$377.5Mn/m |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
FLNA Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'25Filing | Q2'25Filing | Q1'2510-Q | Q4'24Filing | Q3'24Filing |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$3.9Mn/m | -$8.9Mn/m | -$9.7Mn/m | -$6.2Mn/m | -$4.9Mn/m | -$11.3Mn/m | -$61.3Mn/m | -$18.3Mn/m |
| Depreciation & Amortization | $300K+50.0% | $243K+10.5% | $334K+198.2% | $200K-13.8% | $200K-43.8% | $220K-40.9% | $112K-68.5% | $232K-40.8% |
| Stock-Based Compensation | $4.1M-11.2% | $4.1M-22.1% | N/A | $4.4M-21.5% | $4.6M+76.0% | $5.2M+123.8% | N/A | $5.6M+491.0% |
| Capital Expenditures | $21Kn/m | N/A | $501K+778.9% | $80K+370.6% | $0-100.0% | $0n/m | $57K+39.0% | $17K-22.7% |
| Free Cash Flow | -$3.9Mn/m | N/A | -$10.2Mn/m | -$6.3Mn/m | -$4.9Mn/m | -$11.3Mn/m | -$61.3Mn/m | -$18.3Mn/m |
| Investing Cash Flow | -$21Kn/m | N/A | -$501Kn/m | -$80Kn/m | $0n/m | $0n/m | -$57Kn/m | -$17Kn/m |
| Financing Cash Flow | -$16Kn/m | -$51K-156.7% | -$329K-135.8% | $0n/m | $0-100.0% | $90K-99.6% | $918K-19.7% | $0-100.0% |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
FLNA Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'25Filing | Q2'25Filing | Q1'2510-Q | Q4'24Filing | Q3'24Filing |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -13.5%+36.8pp | -15.2%+3.2pp | -16.9%+2.1pp | -13.3%+3.5pp | -50.3%-53.5pp | -18.3%-50.2pp | -18.9%-3.7pp | -16.8%-0.2pp |
| Return on Assets | -8.3%+24.4pp | -9.5%+7.1pp | -10.6%+6.9pp | -8.3%+4.2pp | -32.7%-35.2pp | -16.6%-32.7pp | -17.5%-3.7pp | -12.5%+2.4pp |
| Current Ratio | 2.08-0.3x | 2.19-6.9x | 2.23-9.4x | 2.27-1.3x | 2.43-1.6x | 9.08+7.3x | 11.62+2.5x | 3.55-5.1x |
| Liabilities-to-Equity | 0.63+0.1x | 0.59+0.5x | 0.59+0.5x | 0.59+0.2x | 0.54+0.3x | 0.10-0.9x | 0.080.0x | 0.34+0.2x |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Debt-to-Equity, Asset Turnover, FCF Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Filana Therapeutics, Inc. FLNA | FY2025 | N/A | -$91.0M | N/A | $27.6M | — |
| Aligos Therapeutics, Inc. ALGS | FY2025 | $2.2M | -$24.2M | N/A | $31.3M | 52/100 |
| Adicet Bio, Inc. ACET | FY2025 | N/A | -$116.8M | N/A | $29.0M | — |
| Metagenomi Therapeutics, Inc. MGX | FY2025 | $25.2M | -$87.9M | N/A | $29.8M | 49/100 |
| Briacell Therapeutics Corp. BCTX | FY2026 | N/A | -$34.9M | N/A | $27.9M | — |
| Polyrizon Ltd. PLRZ | FY2025 | N/A | -$3.3M | N/A | $27.0M | — |
Where Filana Therapeutics, Inc. Ranks
Frequently Asked Questions
No, Filana Therapeutics, Inc. (FLNA) reported a net loss of $91.0M in fiscal year 2025.
Filana Therapeutics, Inc. (FLNA) had EBITDA of -$94.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
Filana Therapeutics, Inc. (FLNA) has a return on equity of -122.3% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
Filana Therapeutics, Inc. (FLNA) recorded an outflow of $32.8M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
Filana Therapeutics, Inc. (FLNA) recorded an outflow of $32.3M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
Filana Therapeutics, Inc. (FLNA) had $118.4M in total assets as of fiscal year 2025, including both current and long-term assets.
Filana Therapeutics, Inc. (FLNA) invested $581K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
Filana Therapeutics, Inc. (FLNA) invested $26.6M in research and development during fiscal year 2025.
Filana Therapeutics, Inc. (FLNA) had a current ratio of 2.23 as of fiscal year 2025, which is generally considered healthy.
Filana Therapeutics, Inc. (FLNA) had a liabilities-to-equity ratio of 0.59 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
Filana Therapeutics, Inc. (FLNA) had a return on assets of -76.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
Filana Therapeutics, Inc. (FLNA) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $27.6M as of Nov 4, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Filana Therapeutics, Inc. (FLNA) has no price-to-sales ratio at the moment: no revenue reported. The market capitalization is $27.6M as of Nov 4, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
At the end of fiscal year 2025, Filana Therapeutics, Inc. (FLNA) held $95.5M in cash, cash equivalents and investments, and reported an operating cash outflow of $32.3M over that year. Dividing the one by the other, the reported balance equals about 36 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
Filana Therapeutics, Inc. (FLNA) has a Piotroski F-Score of 2 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Filana Therapeutics, Inc. (FLNA) reported a net loss of $91.0M while operations used $32.3M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.